Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial

Arthur Vandenbark, Yuan K. Chou, Ruth Whitham, Michele Mass, Abigail Buenafe, Diane Liefeld, Daniel Kavanagh, Shelley Cooper, George A. Hashim, Halina Offner, Dennis Bourdette

Research output: Contribution to journalArticle

175 Citations (Scopus)

Abstract

A T-cell receptor (TCR) peptide vaccine from the Vβ5.2 sequence expressed in multiple sclerosis (MS) plaques and on myelin basic protein (MBP)-specific T cells boosted peptide-reactive T cells in patients with progressive MS. Vaccine responders had a reduced MBP response and remained clinically stable without side effects during one year of therapy, whereas nonresponders had an increased MBP response and progressed clinically. Peptide-specific T helper 2 cells directly inhibited MBP-specific T helper 1 cells in vitro through the release of interleukin-10, implicating a bystander suppression mechanism that holds promise for treatment of MS and other autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)1109-1115
Number of pages7
JournalNature Medicine
Volume2
Issue number10
DOIs
StatePublished - Oct 1996

Fingerprint

Myelin Basic Protein
T-Cell Antigen Receptor
Multiple Sclerosis
Peptide T
Peptides
T-cells
Bystander Effect
T-Lymphocytes
Th2 Cells
Th1 Cells
Subunit Vaccines
Therapeutics
Interleukin-10
Autoimmune Diseases
Vaccines

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Treatment of multiple sclerosis with T-cell receptor peptides : Results of a double-blind pilot trial. / Vandenbark, Arthur; Chou, Yuan K.; Whitham, Ruth; Mass, Michele; Buenafe, Abigail; Liefeld, Diane; Kavanagh, Daniel; Cooper, Shelley; Hashim, George A.; Offner, Halina; Bourdette, Dennis.

In: Nature Medicine, Vol. 2, No. 10, 10.1996, p. 1109-1115.

Research output: Contribution to journalArticle

Vandenbark, Arthur ; Chou, Yuan K. ; Whitham, Ruth ; Mass, Michele ; Buenafe, Abigail ; Liefeld, Diane ; Kavanagh, Daniel ; Cooper, Shelley ; Hashim, George A. ; Offner, Halina ; Bourdette, Dennis. / Treatment of multiple sclerosis with T-cell receptor peptides : Results of a double-blind pilot trial. In: Nature Medicine. 1996 ; Vol. 2, No. 10. pp. 1109-1115.
@article{c5d85771067749ddb26b6bc5078ceddc,
title = "Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial",
abstract = "A T-cell receptor (TCR) peptide vaccine from the Vβ5.2 sequence expressed in multiple sclerosis (MS) plaques and on myelin basic protein (MBP)-specific T cells boosted peptide-reactive T cells in patients with progressive MS. Vaccine responders had a reduced MBP response and remained clinically stable without side effects during one year of therapy, whereas nonresponders had an increased MBP response and progressed clinically. Peptide-specific T helper 2 cells directly inhibited MBP-specific T helper 1 cells in vitro through the release of interleukin-10, implicating a bystander suppression mechanism that holds promise for treatment of MS and other autoimmune diseases.",
author = "Arthur Vandenbark and Chou, {Yuan K.} and Ruth Whitham and Michele Mass and Abigail Buenafe and Diane Liefeld and Daniel Kavanagh and Shelley Cooper and Hashim, {George A.} and Halina Offner and Dennis Bourdette",
year = "1996",
month = "10",
doi = "10.1038/nm1096-1109",
language = "English (US)",
volume = "2",
pages = "1109--1115",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Treatment of multiple sclerosis with T-cell receptor peptides

T2 - Results of a double-blind pilot trial

AU - Vandenbark, Arthur

AU - Chou, Yuan K.

AU - Whitham, Ruth

AU - Mass, Michele

AU - Buenafe, Abigail

AU - Liefeld, Diane

AU - Kavanagh, Daniel

AU - Cooper, Shelley

AU - Hashim, George A.

AU - Offner, Halina

AU - Bourdette, Dennis

PY - 1996/10

Y1 - 1996/10

N2 - A T-cell receptor (TCR) peptide vaccine from the Vβ5.2 sequence expressed in multiple sclerosis (MS) plaques and on myelin basic protein (MBP)-specific T cells boosted peptide-reactive T cells in patients with progressive MS. Vaccine responders had a reduced MBP response and remained clinically stable without side effects during one year of therapy, whereas nonresponders had an increased MBP response and progressed clinically. Peptide-specific T helper 2 cells directly inhibited MBP-specific T helper 1 cells in vitro through the release of interleukin-10, implicating a bystander suppression mechanism that holds promise for treatment of MS and other autoimmune diseases.

AB - A T-cell receptor (TCR) peptide vaccine from the Vβ5.2 sequence expressed in multiple sclerosis (MS) plaques and on myelin basic protein (MBP)-specific T cells boosted peptide-reactive T cells in patients with progressive MS. Vaccine responders had a reduced MBP response and remained clinically stable without side effects during one year of therapy, whereas nonresponders had an increased MBP response and progressed clinically. Peptide-specific T helper 2 cells directly inhibited MBP-specific T helper 1 cells in vitro through the release of interleukin-10, implicating a bystander suppression mechanism that holds promise for treatment of MS and other autoimmune diseases.

UR - http://www.scopus.com/inward/record.url?scp=16044361810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16044361810&partnerID=8YFLogxK

U2 - 10.1038/nm1096-1109

DO - 10.1038/nm1096-1109

M3 - Article

C2 - 8837609

AN - SCOPUS:16044361810

VL - 2

SP - 1109

EP - 1115

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 10

ER -